New pill could tame rare, aggressive tumors without surgery
NCT ID NCT01876082
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested the drug pazopanib against a standard chemotherapy combination (vinblastine and methotrexate) in 72 adults with progressive desmoid tumors. Desmoid tumors are non-cancerous but can grow aggressively and come back after surgery. The study measured how many patients stayed alive and tumor-free at 6 months. Pazopanib is a daily pill that blocks blood vessel growth, while the comparison treatment is given by injection. The goal is to find a less invasive way to control these tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pazopanib (a targeted cancer drug taken as a pill)
- What this could lead to
- If it works, pazopanib could offer a new, pill-based option to control desmoid tumors without surgery or stronger chemotherapy.
- What could go wrong
- This is a phase 2 trial with only 72 people, so results are preliminary. Pazopanib may not work better than existing treatments and can cause side effects like fatigue, high blood pressure, and liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE DESMOIDS TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonié
Bordeaux, Aquitaine, 33000, France